Bouma MJ, van Iterson M, Janssen B, Mummery CL, Salvatori DCF, Freund C.
Stem Cell Reports. 2017 May 9;8(5):1340-1353.
This article with the contributions of GenomeScan’s Bart Janssen compares Teratoma assay with the PluriTest and the hPSC ScoreCard assay as its in vitro alternatives.
“While normal hPSCs gave rise to typical teratomas, the xenografts of the hECs and the hiPSCs with reactivated reprogramming transgenes were largely undifferentiated and malignant. The hPSC ScoreCard assay confirmed the line-specific differentiation propensities in vitro. However, when undifferentiated cells were analyzed by the PluriTest, only hECs were identified as abnormal whereas all other cell lines were indistinguishable and resembled normal hPSCs. Our results indicate that pluripotency assays are best selected on the basis of intended downstream applications.”
